The following articles and press releases are to provide information on the current status of the company as well as pertinent related articles on the EP industry. In addition, we also want to provide a historical perspective on the over 20 years of development that has preceded the advent of the new Huygens™ Smart Catheter and the Proteus™ Robotic Guidance System. NKC is very proud of its achievements in the field of advancing catheter mapping tools and guidance systems for the Electrophysiology field.
Specifically, all the articles related to the CGCI technology prior to 2015 relate to the prior work of the company under the Magnetecs banner and do not reflect the current NKC efforts except to show that the company has the ability to move their technology from invention to regulatory acceptance and then to real-world operation. The company is bringing this same expertise to bear on its revolutionary new Smart Catheter and Robotic Guidance System.
If you have any questions regarding any information you find here, please contact us at: email@example.com
NKC delivers its end of the year development report for the 2022.
NKC has released its fourth quarter report for 2022.
NKC has released its third quarter development report for 2022.
NKC reports on the acquisition St. Jude Medical by Abbott.
NKC Announces Upcoming Animal Study for Clinical Validation of its Huygens™ – Proteus™ Robotic Arm Surgical Platform
NKC announces animal study to be performed to provide clinical validation of its Huygens™ technology.
NKC has announced the completion of the Phase One development for its new Huygens™ Smart Catheter and Proteus™ Robotic Arm Platform.
Global consulting firm Frost & Sullivan looks at potential market impact of the Neuro-Kinesis SmartBrain Retractor technology.
The development of SMART technologies for surgical tools coupled with advances in robotics is providing a revolution in creating better, safer and less invasive surgical options for patients.
The global catheter market expected to rise to $77.7B by 2026 with an average CAGR of 9.7% over the forecast period.
The CGCI platform has successfully undergone a Good Laboratory Practice (GLP) animal study in advance of its next stage clinical trials.